Literature DB >> 18922646

Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution.

Kate Parker1, Eve Gallop-Evans, Louise Hanna, Malcolm Adams.   

Abstract

PURPOSE: To assess the clinical outcomes after concurrent cisplatin chemotherapy and radiotherapy (RT) followed by high-dose-rate brachytherapy for locally advanced carcinoma of the cervix and perform a multivariate analysis of the prognostic factors. METHODS AND MATERIALS: The outcomes were analyzed for all women treated between 1999 and 2004 with concurrent cisplatin chemotherapy and RT followed by high-dose-rate brachytherapy. Kaplan-Meier analysis was used for overall survival (OS), local control (LC), and distant control (DC). The Cox proportional hazards model was used to perform multivariate analysis of the prognostic variables.
RESULTS: The standard regimen comprised whole pelvic external RT 45 Gy in 25 fractions with concurrent weekly cisplatin 40 mg/m(2), followed by four high-dose-rate brachytherapy insertions of 6 Gy. Patients with radiologically enlarged para-aortic lymph nodes underwent extended-field RT. Of 92 patients, the OS rate was 72% at 2 years and 55% at 5 years. The LC rate was 76% at 2 years and 67% at 5 years. The DC rate was 68% at 2 years and 48% at 5 years. The most important prognostic factor for OS, LC, and DC was the pretreatment hemoglobin. For OS, the tumor size and the presence of enlarged lymph nodes were also important. For LC, the number of brachytherapy insertions was important; and for DC, the number of chemotherapy treatments was important. Of the patients, 4% experienced late Grade 3 or 4 toxicity.
CONCLUSION: The results of our study have shown that the regimen is effective, with acceptable long-term side effects. In this cohort, the most important prognostic factor was the pretreatment hemoglobin level, a disease-related factor. However, more effective systemic treatments are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922646     DOI: 10.1016/j.ijrobp.2008.06.1920

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

1.  Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data.

Authors:  Yun Liang; Karen Messer; Brent S Rose; John H Lewis; Steve B Jiang; Catheryn M Yashar; Arno J Mundt; Loren K Mell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-14       Impact factor: 7.038

2.  A new laparoscopic method of bowel radio-protection before pelvic chemoradiation of locally advanced cervix cancers.

Authors:  E Leblanc; F Narducci; L Bresson; J Durand-Labrunie; S Taieb; E Vanlerenberghe; I Farre; P Nickers
Journal:  Surg Endosc       Date:  2014-05-02       Impact factor: 4.584

Review 3.  American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer.

Authors:  Jyoti Mayadev; Akila Viswanathan; Yu Liu; Chin-Shang Li; Kevin Albuquerque; Antonio L Damato; Sushil Beriwal; Beth Erickson
Journal:  Brachytherapy       Date:  2017 Jan - Feb       Impact factor: 2.362

4.  Long-term results and prognostic factors in patients with stage III-IVA squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy from a single institution study.

Authors:  Wataru Kudaka; Yutaka Nagai; Takafumi Toita; Morihiko Inamine; Kozue Asato; Tomoko Nakamoto; Akihiko Wakayama; Takuma Ooyama; Akemi Tokura; Sadayuki Murayama; Yoichi Aoki
Journal:  Int J Clin Oncol       Date:  2012-08-18       Impact factor: 3.402

5.  Tumor growth patterns on magnetic resonance imaging and treatment outcomes in patients with locally advanced cervical cancer treated with definitive radiotherapy.

Authors:  Shintaro Tsuruoka; Masaaki Kataoka; Yasushi Hamamoto; Akifumi Tokumasu; Kotaro Uwatsu; Hiromitsu Kanzaki; Noriko Takata; Hirofumi Ishikawa; Ayaka Ouchi; Teruhito Mochizuki
Journal:  Int J Clin Oncol       Date:  2019-05-11       Impact factor: 3.402

6.  Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.

Authors:  Brent S Rose; Bulent Aydogan; Yun Liang; Mete Yeginer; Michael D Hasselle; Virag Dandekar; Rounak Bafana; Catheryn M Yashar; Arno J Mundt; John C Roeske; Loren K Mell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-17       Impact factor: 7.038

7.  Long-term results and prognostic factors of patients with cervical carcinoma treated with concurrent chemoradiotherapy.

Authors:  Ana Reig; Ismael Membrive; Palmira Foro; Xavier Sanz; Núria Rodríguez; Joan Lozano; Martí Lacruz; Jaume Quera; Enric Fernández-Velilla; Manuel Algara
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

8.  Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.

Authors:  Yan Xiao; Ying-Kun Ren; Hui-Jun Cheng; Li Wang; Su-Xia Luo
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

9.  Using [(18)F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients.

Authors:  Sarah M McGuire; Sudershan K Bhatia; Wenqing Sun; Geraldine M Jacobson; Yusuf Menda; Laura L Ponto; Brian J Smith; Brandie A Gross; John E Bayouth; John J Sunderland; Michael M Graham; John M Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-04-19       Impact factor: 7.038

10.  Clinical Impact of Pelvic Lymph Node Status in Locally Advanced Cervical Cancer Patients Treated by Concurrent Chemoradiation Therapy.

Authors:  Kanyarat Katanyoo; Thaovalai Thavaramara
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.